Latest news for International Isotopes (OTC:INIS) Stock

International Isotopes Inc manufactures a full range of nuclear medicine calibration and reference standards, cobalt teletherapy sources, and other sealed sources. International Isotopes also distributes a varied selection of radioisotopes and radiochemicals for medical and clinical research, and pharmacy compounding. International Isotopes's business consists of four business segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, and Fluorine Products. Geographically, it generates the majority of its revenue from the United States.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

INIS

KINS

The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying

INTL ISOTOPES INC by International Isotopes, Inc.

International Isotopes Inc

Earnings

Small Cap

Press Releases

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR FISCAL YEAR 2023

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FIRST QUARTER OF 2024

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE SECOND QUARTER AND FIRST SIX MONTHS OF 2024

International Isotopes Inc. and Phantech Medical Launch PhanQual to Revolutionize Calibration Sources for Pre-Clinical Imaging

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2024

International Isotopes, Inc. Announces the Amendment of the Acquisition of the AMICI, Inc. Product Line

Real Estate

International Isotopes, Inc. Expands Operational Footprint with Strategic Land Acquisition and Additional New Facility Lease Agreement

International Isotopes

The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.

<h3>Kingstone Companies </h3>

<ul>
	<li>The Trade: Kingstone Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KINS#NASDAQ">KINS</a>) Chief Operating Officer Meryl S Golden <a href="https://www.benzinga.com/quote/KINS/analyst-ratings"> acquired a total of 5,811 shares </a> an average price of $1.98. To acquire these shares, it cost around $11,507.</li>
	<li>What&rsquo;s Happening: Kingstone Companies posted a wider-than-expected quarterly loss.</li>
	<li>What Kingstone Companies Does: Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company.</li>
</ul>

<h3>International Isotopes </h3>

<ul>
	<li>The Trade: International Isotopes Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/INIS#OTC">INIS</a>) President Shahe Bagerdjian <a href="https://www.benzinga.com/quote/VNRX/analyst-ratings"> acquired a total of 3,950 shares </a> at an average price of $0.05. The insider spent around $197.50.</li>
	<li>What&rsquo;s Happening: The company said revenue for the six months ended June 30, 2023, was $6,201,700, up from $5,242,249 for the year-ago period.</li>
	<li>What International Isotopes Does: International Isotopes Inc manufactures a full range of nuclear medicine calibration and reference standards, cobalt teletherapy sources, and other sealed sources.</li>
</ul>

<h3>Cue Biopharma</h3>

<ul>
	<li>The Trade: Cue Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) President and CSO Anish Suri <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 4,000 shares </a> at an average price of $2.76. To acquire these shares, it cost around $11,040.</li>
	<li>What&rsquo;s Happening: Cue Biopharma posted upbeat quarterly results.</li>
	<li>What Cue Biopharma Does: Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.</li>
</ul>

&nbsp;

Check This Out: <a href="https://www.benzinga.com/news/earnings/23/08/34107892/investor-sentiment-improves-after-s-p-500-closes-sharply-higher"> Investor Sentiment Improves After S&amp;P 500 Closes Sharply Higher </a>

Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Comments

International Isotopes

News

Latest news for International Isotopes (OTC:INIS) Stock

Wednesday, August 30, 2023

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga